Piramal Pharma Solutions Achieves Regulatory Milestone
Piramal Pharma Solutions has successfully implemented a comprehensive action plan aimed at complying with evolving regulatory requirements related to nitrosamine impurities. The company's commitment to maintaining high standards of patient safety and product quality is integral to its operations.
Understanding Nitrosamines in Pharmaceuticals
Nitrosamines are unintended byproducts with potential carcinogenic risks found in specific medications. As global guidelines regarding nitrosamine drug substance-related impurities (NDSRIs) evolve, pharmaceutical companies like Piramal must adapt their operations to remain compliant. This involves a proactive, multi-step strategy designed to ensure regulatory alignment and safeguard patient health.
Proactive Compliance Strategy
At the forefront of this approach is a cross-functional core team made up of experts from various departments including Regulatory Affairs, Central Quality, R&D, and Manufacturing. These professionals interpret regulatory guidance as it emerges, ensuring that all operations align with international NDSRI standards.
Key Aspects of the Company’s Action Plan
A significant step in achieving compliance includes the issuance and regular updating of a Position Paper. This document serves as a centralized guide that delineates roles and responsibilities, assisting site teams in navigating the challenges presented by new regulatory requirements.
Risk Assessment and Testing Initiatives
Prioritizing safety assessments for all applicable drug substances and products has been a cornerstone of the company’s compliance journey. Each identified product undergoes rigorous confirmatory testing to evaluate its safety and regulatory implications. Presently, all commercial products under Piramal Pharma Limited adhere to global regulatory standards, while some customer products await final approval.
The action plan also prioritizes the establishment of testing capabilities within the company’s key facilities. This investment includes the qualification of external laboratories to complement in-house testing, bolstering efforts to meet increasingly stringent regulatory demands. The enhancement of testing facilities is especially crucial at the Ahmedabad and Digwal sites, enabling rapid compliance with safety standards and minimizing risks associated with impurities.
Commitment to Patient Safety
"At Piramal Pharma Solutions, our priority is ensuring patient well-being. Achieving regulatory compliance for nitrosamine impurities showcases our dedication to operational excellence and patient safety," shared Rashida Najmi, Chief Quality Officer of Piramal Pharma Limited. The proactive capability enhancements establish a solid foundation for adapting to global NDSRI standards.
As these international guidelines continue to develop, Piramal Pharma Solutions is steadfast in its commitment to maintaining the highest standards of pharmaceutical quality and patient safety.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) operates as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive development and manufacturing services throughout the drug life cycle. With a well-integrated network across North America, Europe, and Asia, PPS offers a broad spectrum of services, including drug discovery, clinical trials, and the production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Its specialization extends to developing highly potent APIs, antibody-drug conjugates, and biologics, including vaccines and gene therapies.
Frequently Asked Questions
What are nitrosamines, and why are they significant?
Nitrosamines are potential carcinogenic compounds that can inadvertently develop during pharmaceutical manufacturing. Ensuring their control is critical to protect patient safety.
How does Piramal Pharma Solutions ensure compliance with regulations?
The company employs a dedicated cross-functional team to interpret regulatory guidelines, conducts risk assessments, testing, and invests in advanced capabilities to maintain compliance.
What role does the Position Paper play in compliance?
The Position Paper serves as a detailed guide, clarifying responsibilities and aiding site teams in adhering to evolving regulatory requirements.
Why is in-house testing capability important for Piramal?
In-house testing enables quicker compliance with safety standards and reduces dependence on external laboratories, ensuring timely product readiness.
How does Piramal prioritize patient safety?
Piramal's commitment to patient safety is reflected in its rigorous testing protocols and proactive measures to ensure regulatory compliance across all its products.
